Integrity Coronary Stent System    

Log In

Forgot Your Password?

Not a member? Click here!

Academic View: Post-market Evaluation: What is Optimal Information Distribution?
Harmonization of the European and the US Experience with the New Requirements
Clinical Trial Design for a New Technology: Limitations of Historical Controls
Carotid, Brachiocephalic and Intracranial Vascular Anatomy: What the Interventionalist Needs to Know
Global Regulatory Harmonization: Future or Fantasy?



A Sprint to Lower BP

The optimal BP to reduce adverse cardiovascular (CV) events is unknown. The SPRINT study randomized 9361 individuals with BP≥130 mmHg and increased CV risk to a target of either <120 mmHg or <140 mmHg. The primary composite outcome of MI, other ACS, stroke, heart failure or death was lower in the <120 mmHg group but this was at the cost of greater rates of hypotension, syncope, electrolyte abnormalities and renal impairment.

For more, click here




IVUS Guided PCI-Standard of Care for Complex Lesions

The clinical impact of IVUS guided as compared to angiography guided PCI remains debatable. A randomized study of 1400 patients undergoing PCI for long coronary lesions with everolimus-eluting stents has indicated that IVUS guidance is associated with lower rates of the composite of major adverse cardiac events, driven by lower risk of ischemia driven TLR.

For more, click here



ABSORB III Confirms Non-inferiority of Bioresorbable Scaffolds

Bioresorbable scaffolds have the potential to overcome many of the limitations of metallic scaffolds such as target lesion failure. The ABSORB III study, comparing an everolimus-eluting bioresorbable vascular (Absorb) scaffold with the everolimus-eluting cobalt-chromium stent has confirmed the non-inferiority of the Absorb scaffold. Interestingly, at the 1-year follow-up, the superiority margin of the trial was not met.

For more, click here




Is Courage Relevant in the FFR Era

The landmark COURAGE study has indicated similar survival in patients undergoing optimal medical therapy (OMT) or OMT plus PCI in patients presenting with angina. The 15-year results of this study from 53% of the original population has continued to confirm the initial conclusions of the study with mortality rates of 25% and 24% in the OMT plus PCI and OMT groups respectively. A tale of caution in interpreting this result is that the COURAGE study was undertaken before the era of FFR guided PCI.

For more, click here



First-in-man Experience of the Transcatheter FORMA Repair System for Treating Severe Tricuspid Regurgitation
- Francisco Campelo-Parada, MD
Selecting the Right FFR in an Unsteady State: Keep It Simple
- Morton Kern, MD
Transcatheter Structural Heart Interventions for the treatment of Chronic Heart Failure
- Dr Josep Rodes Cabau, MD
The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction
- Thomas Engstrøm, MD, DMSci, PhD
Relationship between hospital PTCA volume and in-hospital outcomes: Is it still true 9 years later?
- Christian Spaulding, M.D., FACC, FESC
The EGO-BioFreedom Study
- Stephen Lee, MD
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
- George L. Zorn, III, MD
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement
- Thomas G. Gleason, MD
Valve Thrombosis After TAVR: Frequency, Clinical Recognition, and Management
- Azeem Latib, MD
 Click here to visit the WEBEX archives
Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update
Sigmund Silber, MD
Evaluation of Two-Year Outcomes Following Resolute Integrity Zotarolimus-eluting Stent Implantation
Ronald Caputo, MD
Properties of a Novel Drug Filled Coronary Stent: Impact on Mechanical Strength and Radiopacity
Nicolas Foin, MSc, PhD
Titratable Drug Delivery from Drug-Filled Stents
Rami Tzafriri, MD
Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

Untitled Document
Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension. Analysis From the Dallas Heart Study.
D Tientcheu, et al.
JACC 2015; 66:2159-2169
The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk.
Y Cheng, et al.
JACC 2015; 66:2173-2184
Early and Late Outcomes of Surgical Treatment in Carcinoid Heart Disease.
H Connolly, et al.
JACC 2015; 66:2189-2196
Enhanced Cardiac Regenerative Ability of Stem Cells After Ischemia-Reperfusion Injury. Role of Human CD34+ Cells Deficient in MicroRNA-377.
D Joladarashi, et al.
JACC 2915; 66:2214-2226
Dose–Response Relationship Between Physical Activity and Risk of Heart Failure. A Meta-Analysis.
A Pandey, et al.
Circ 2015; 132:1786-1794
Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus. A Meta-Analysis and Systematic Review.
A Pan, et al.
Circ 2015; 132:1795-1804
Association of Physician Certification in Interventional Cardiology With In-Hospital Outcomes of Percutaneous Coronary Intervention.
P Fiorilli, et al.
Circ 2015; 132:1816-1824
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
S Ellis, et al.
NEJM 2015; 373:1905-1915
Effect of PCI on Long-Term Survival in Patients With Stable Ischemic Heart Disease.
S Sedlis, et al.
NEJM 2015; 373:1937-1946
Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.
D Asch, et al.
JAMA 2015; 314:1926-1935
Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication. A Randomized Clinical Trial.
F Fakhry, et al.
JAMA 2015; 314:1936-1944
Prevalence and Correlates of Myocardial Scar in a US Cohort.
E Turkbey, et al.
JACC 2015; 314:1945-1954
Alcohol Consumption and Cardiovascular Disease, Cancer, Injury, Admission to Hospital, and Mortality: A Prospective Cohort Study.
A Smyth, et al.
The Lancet 2015; 386:1945-1954

Poll Archives

Marc P. Bonaca, MD, MPH
Mark J. Eisenberg, M.D
Justin A. Ezekowitz, M.D
Myeong-Ki Hong, MD. PhD
DAPT Study
Robert W. Yeh, M.D
A Network Meta-Analysis
Michael J. Lipinski, M.D
Mark Crowther, MD, MSc, FRCPC
Gender Disparities - TAVR
Michael A. Gaglia, Jr., M.D
Geeta Gulati1, M.D
The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing TAVR
Romain Didier, M.D
The PCSK9 Inhibitor Revolution
Norman E. Lepor, MD, FACC
Paul K. Whelton, MB, MD, MSc

The ABSORB III trial
Dean J. Kereiakes, MD
ABSORB China Trial
Run-Lin Gao, MD
Bernard Chevalier, MD
Michael Haude, MD
Giora Weisz, MD
Jose PS Henriques, MD
TOTAL: One-Year Outcomes
Sanjit S. Jolly, MD
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset
Steffen Desch, MD
Mark A. Hlatky, MD
Philip M. Urban, MD
Tuxedo: One Year Clinical Results
Upendra Kaul, MD
Bo Xu, MD
IN.PACT SFA: Two-Year Outcomes
John Laird, MD
Thierry Lefevre, MD
SAPIEN 3: One-Year Outcomes
Howard C. Herrmann, MD
John D. Carroll
Evaluation of Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic Stenosis:
Tomohiko Taniguchi, MD
1-Year Results from the PARTNER II Valve-in-Valve Registry
Danny Dvir, MD
1 year results of the TOTAL trial
TOTAL Investigators
RevElution Clinical Trial
Stephen G. Worthley, MBBS, PhD
CoreValve Data
Jeffrey J. Popma, MD
TWENTE Five-Year Outcomes
Clemens von Birgelen, MD, PhD
The Nordic-Baltic Bifurcation Study III
Matti Niemela, MD
Cheol Woong Yu1, MD, PhD
Pivotal Trial
James B. Hermiller Jr, MD
Neointimal Modification with Scoring-Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug-Eluting Coronary Stents
Robert A. Byrne, MD
Alignment of DNR Status with Patients Likelihood of Favorable Neurological Survival after In-hospital Cardiac Arrest
Timothy Fendler, MD, MS
A serial multivessel OCT study
Lorenz Raber, MD, MS

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD


FDA Approves COBRA-REDUCE Trial for CeloNova’s Cobra PzF Stent System

Miracor Medical Systems Launches PICSO Impulse System in Asia

St. Jude Medical’s 27-mm and 29-mm Portico TAVR Valves Gain CE Mark Approval

Avinger Receives Financing to Support Launch of Pantheris

pToWin Assesses Phenox’s pConus Bifurcation Aneurysm Device in Wide-Neck Intracranial Aneurysms

FDA Approves Cook’s Zenith Alpha Thoracic Graft

Medtronic’s Arc Support Catheter Launched for Solitaire Stent Retriever in Acute Ischemic Stroke Treatment

CE mark for 27mm and 29mm of Portico TAVI valves

First Patient Enrolled in Phase 4 of AUGUSTUS Trial to Evaluate Safety of Eliquis

Medicure Seeks STEMI Indication for Aggrastat in United States

Nipro to Acquire Infraredx

CeloNova’s e-COBRA Clinical Registry Begins Enrollment in France

Valtech’s Cardioband Mitral Reconstruction System Receives CE Mark Approval for TMVR

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

Gore Unveils Q50® PLUS Stent Graft Balloon Catheter

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

TriVascular Announces First Patient Enrolled in the LUCY Study

Boston Scientific Announces FDA Approval of Innova™ Vascular Self-Expanding Stent System

Medtronic to Acquire Twelve, Inc., Developer of Transcatheter Mitral Valve Replacement Device

QualiMed's QBX 5-F Balloon-Expandable Stent System Launched in Europe

FDA Clears Phase-2 Trial for Hemostemix Drug to Treat CLI
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2015 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2015, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb